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Introduction
In 1996, the Center for Disease Control and Prevention
(CDC), the American Academy of Pediatrics, and the
American College of Obstetricians and Gynecologists
recommended intrapartum antimicrobial prophylaxis for
women with late antenatal group B Streptococcus (GBS)
rectovaginal colonization or, alternatively, with mater-
nal risk factors for transmitting the infection [1–3]. The
CDC Active Bacterial Core Surveillance system reported
that the incidence of early-onset GBS disease (0–6 days
of life) declined by 65% as result of implementation of
these recommendations. Adoption of a universal screen-
ing strategy for women at 35–37 weeks’ gestation in
2002 resulted in a further reduction of 31% in 2004.
For preterm infants, the case-fatality rates were 23% and
9% for early-onset and late-onset cases, respectively,
compared with 4% and 0%, respectively, for term infants.
At Parkland Memorial Hospital, Dallas, Texas (USA), the
incidence of early-onset GBS disease in 2004 was 0.4
cases per 1,000 live births, down from 2.85 cases before
the introduction of screening and prophylaxis [4].
GBS is a leading cause of illness and death among
newborns in the United States. Approximately 10–30% of
pregnant women are found to be colonized with GBS
when tested using the culture method [1,5]. This percent-
age is consistent with other results obtained using similar
molecular methods [6,7]. GBS can be transmitted to the
newborn if antibiotics are not administered 2–4 hours
prior to delivery [8]. Infants infected with GBS may
suffer mental retardation and hearing or vision loss.
The 2002 CDC guidelines call for prenatal GBS
screening of all pregnant women at 35–37 weeks’ ges-
tation [9]. The current standard methods for detection
of GBS consist of selective broth cultures of combined
vaginal and anal specimens. Although these methods
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are sensitive and specific, they are time-consuming,
requiring 48–72 hours, and also depend on the pres-
ence of viable microorganisms. However, many women
deliver preterm, lack prenatal care, or become colonized
with GBS between 35 weeks’ gestation and delivery. For
these women, culture-based results will not be avail-
able in time, resulting in a risk of infection or unneces-
sary treatment with antibiotics. Hence, an alternative,
rapid, sensitive and specific method for detection of GBS
from clinical specimens in pregnant women is needed
to allow timely treatment of neonates and to reduce
unnecessary worry about GBS infection between 35
weeks’ gestation and delivery. We evaluated pregnant
women who had negative results using a culture-based
method at 35 weeks’ gestation, and had cultures and
real-time polymerase chain reaction (RT-PCR) tests after
39 weeks’ gestation.
Materials and Methods
This prospective, observational, pilot study was con-
ducted at Cathay General Hospital with institutional
board approval.
During prenatal visits to the obstetrics clinic of 
the Si-Jhih branch of Cathay General Hospital, preg-
nant women were informed about the study and asked
about their willingness to participate. From 2006 to
2007, we recruited 150 pregnant women who had nega-
tive results on culture-based GBS screening at 35 weeks’
gestation. They received another rectovaginal culture
and RT-PCR GBS test at 39 weeks’ gestation.
Two swabs were used and both were first inserted
in the vaginal mucosa and then the anal sphincter. One
swab was used for culture and one for polymerase chain
reaction (PCR). The same swab was inserted approxi-
mately 2.5 cm beyond the anal sphincter and gently
rotated to sample the anal crypts. All rectovaginal swabs
were cultured in 5 mL of LIM broth (Todd-Hewitt broth
containing 10 μg of colistin per milliliter and 15 μg of
nalidixic acid per milliliter) and incubated overnight at
room temperature. Blood agar plates were then inocu-
lated with 50 μL of broth. The plates were inoculated at
37°C in 5% carbon dioxide (v/v) for 24–48 hours.
Species identification of β-hemolytic colonies was per-
formed by agglutination with a streptococcal grouping
kit (Prolex Streptococcal Grouping Latex Kit; Pro-Lab
Diagnostics, Richmond Hill, Ontario, Canada). The
procedures were performed according to the manu-
facturer’s instructions.
For PCR, the second swab was placed in a sample
preparation buffer tube and cut. This was allowed to
stand for 5 minutes and then vortexed at high speed
for 15 seconds. A total of 50 μL of solution was added
to the lysis tube, vortexed at high speed for 5 minutes,
centrifuged for 2–5 seconds, and heated at 95°C for 
2 minutes. The lysis tube was placed on ice or a cooling
block for DNA extraction. A total of 25 μL of diluents,
which were provided in the IDI-Strep B kit (Becton
Dickinson & Co., Franklin Lakes, NJ, USA), were added,
and 1.5 μL of the lysate solution was transferred to the
master mix tube, centrifuged for 5–10 seconds, and
vortexed for 2–5 seconds. The tube was placed on a
SmartCycler cooling block (Cepheid, Sunnyvale, CA,
USA) at 2–8°C until ready to load and reconstituted
with one master mix for each specimen. One positive
control and one negative control were reconstituted by
adding 25 μL of diluents to each tube, and the positive
control/negative control tubes were centrifuged for
5–10 seconds, vortexed for 2–5 seconds and placed on
a SmartCycler cooling block at 2–8°C until ready to
load. Each reaction tube was inserted in a SmartCycler
I-Core module and the results were available in less
than 45 minutes. A Cepheid SmartCycler DNA detec-
tion system was used for RT-PCR analysis. We use the
IDI-Strep B test kit with a sensitivity of 93.9%, specificity
of 95.8%, positive predictive value (PPV) of 83.8%, and
negative predictive value (NPV) of 98.5%, with FDA
approval [10].
The IDI-Strep B test kit genetic target for GBS iden-
tification is the cfb gene. This gene encodes the CAMP
factor, which is present in virtually all GBS isolates.
Detection of the CAMP factor is used for presumptive
identification of GBS by biochemical methods. The cfb
gene is well conserved within this species. Primers
amplify a conserved region of 154-bp fragment of the
cfb gene. The amplified DNA targets are detected using
the molecular beacons FAM at the 5 end and quencher
DABCYL at the 3 end.
Results of the culture and RT-PCR methods were
compared for each specimen. For discrepant results,
RT-PCR was repeated twice to confirm the initial find-
ings. The sensitivity, specificity, and PPV/NPV were 
calculated for the RT-PCR assay.
Results
A total of 150 pregnant women with negative GBS
findings at 35 weeks’ gestation using the culture-based
method gave informed consent for the study and were
enrolled. They received repeat rectovaginal GBS culture
and RT-PCR tests after 39 weeks’ gestation.
The median maternal age was 26 years, median
gestational age was 39.3 weeks, median gravida 3, and
median parity 1 (Table 1).
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Three of the 150 women were found to be positive
for GBS after 39 weeks. Two of these were positive using
both the culture and RT-PCR methods, while the other
had a negative culture result, but a positive RT-PCR
result. The RT-PCR result was repeated twice for con-
firmation.
Table 2 shows the comparison between the culture
method and RT-PCR. The sensitivity of the RT-PCR
assay was 100% and specificity was 99.3%. The PPV
was 66.7%, and the NPV was 100%.
Discussion
We demonstrated that 2% of pregnant women with
negative results on GBS culture screening at 35 weeks’
gestation had positive results 4 weeks later, demon-
strated by culture or RT-PCR.
According to CDC guidelines [9], pregnant women
with preterm labor need a GBS culture every 4 weeks
until delivery, and term pregnant women with negative
GBS cultures who are within 4 weeks of delivery do not
require intrapartum antibiotic prophylaxis. However,
these pregnant women are at risk of newly colonized
GBS, meaning that some neonates will still be at risk 
of GBS infection if their mothers have only one nega-
tive GBS culture screening at 35–37 weeks gestation.
The total hands-on time for the two tests is similar,
but it takes longer to obtain the results of culture-based
screening (48–72 hours) than of RT-PCR (2 hours). 
In emergencies such as preterm delivery, rapid results
are needed to lower infant morbidity and mortality, and
RT-PCR provides a simple, rapid result with sufficient
sensitivity for detecting GBS colonization in pregnant
women.
Our study produced one discrepant result, with 
a negative culture result and a positive RT-PCR result.
This could have occurred because RT-PCR detects only
bacterial genes, not viable bacteria colonies. The inabil-
ity of a culture to detect small bacterial colonies or 
the presence of antagonistic microorganisms can also
cause discrepant results. Specimens can sometimes be
culture-positive and RT-PCR-negative, if rare mutant
GBS colonies are present.
A bacterial culture is always required, especially when
an antibiotic is needed. Penicillin is the drug of choice
for prophylaxis and treatment of GBS infection, and no
resistance to this agent has so far been reported among
GBS isolates. One disadvantage of RT-PCR is that it
cannot indicate antibiotic susceptibility [11,12]. How-
ever, even with penicillin-resistant or rare GBS colonies,
PCR can be used to confirm the DNA sequence to
identify the organism and so aid with the choice of
appropriate antibiotics.
According to our results, 2% of pregnant women with
negative GBS cultures at 35 weeks’ gestation had posi-
tive results based on either culture or RT-PCR findings
4 weeks later. We suggest that GBS testing should be
repeated 4 weeks after an initial negative screening result
at 35–37 weeks’ gestation. RT-PCR can be considered
suitable for use at the time of labor, because it can pro-
vide simple, rapid results and is sufficiently sensitive to
detect GBS.
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Table 1. Patient demographics
Characteristic Value
Maternal age, median (range) (yr) 26 (18–44)
Gestational age, median (range) (wk) 39.3 (39–40)
Gravidity, median (range) 3 (1–5)
Parity, median (range) 1 (0–3)
Table 2. Sensitivity, specificity, and positive and negative 
predictive values of the culture method compared with 
real-time polymerase chain reaction (RT-PCR) for detec-
tion of group B Streptococcus (GBS)
Culture method
GBS detection methods
Positive Negative
RT-PCR method
Positive 2 1
Negative 0 147
Sensitivity 2/2 (100%)
Specificity 147/148 (99.3%)
Positive predictive value 2/3 (66.7%)
Negative predictive value 147/147 (100%)
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